Background And Hypothesis: Around 20% of people at clinical high risk (CHR) for psychosis later develop a psychotic disorder, but it is difficult to predict who this will be. We assessed the incidence of hearing speech (termed speech illusions [SIs]) in noise in CHR participants and examined whether this was associated with adverse clinical outcomes.

Study Design: At baseline, 344 CHR participants and 67 healthy controls were presented with a computerized white noise task and asked whether they heard speech, and whether speech was neutral, affective, or whether they were uncertain about its valence. After 2 years, we assessed whether participants transitioned to psychosis, or remitted from the CHR state, and their functioning.

Study Results: CHR participants had a lower sensitivity to the task. Logistic regression revealed that a bias towards hearing targets in stimuli was associated with remission status (OR = 0.21, P = 042). Conversely, hearing SIs with uncertain valence at baseline was associated with reduced likelihood of remission (OR = 7.72. P = .007). When we assessed only participants who did not take antipsychotic medication at baseline, the association between hearing SIs with uncertain valence at baseline and remission likelihood remained (OR = 7.61, P = .043) and this variable was additionally associated with a greater likelihood of transition to psychosis (OR = 5.34, P = .029).

Conclusions: In CHR individuals, a tendency to hear speech in noise, and uncertainty about the affective valence of this speech, is associated with adverse outcomes. This task could be used in a battery of cognitive markers to stratify CHR participants according to subsequent outcomes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016413PMC
http://dx.doi.org/10.1093/schbul/sbac163DOI Listing

Publication Analysis

Top Keywords

chr participants
16
uncertain valence
12
speech illusions
8
people clinical
8
clinical high
8
high risk
8
associated adverse
8
assessed participants
8
hearing sis
8
sis uncertain
8

Similar Publications

Background: Eating disorders (EDs) are among the least studied mental disorders in individuals at clinical high risk for psychosis (CHR-P). The primary aim (a) of this systematic review and meta-analysis was to identify factors predicting ED diagnoses in CHR-P individuals. The secondary aim (b) was providing a comprehensive clinical description of individuals with both CHR-P and EDs/ED-related symptoms.

View Article and Find Full Text PDF

Autistic symptoms and clinical features of individuals at clinical high risk for psychosis and first-episode psychosis.

Asian J Psychiatr

December 2024

Department of Psychiatry, Tohoku University Hospital, Sendai, Miyagi, Japan; Department of Psychiatry, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan. Electronic address:

Introduction: Autistic symptoms in schizophrenia are reportedly associated with cognitive and social functions. However, few studies have investigated the association between autistic symptoms and clinical features in individuals with a clinical high risk for psychosis (CHR-P) and first-episode psychosis (FEP). We aimed to determine the association between autistic symptoms and clinical features in a cohort of individuals with CHR-P or FEP.

View Article and Find Full Text PDF

When to stop immunotherapy for advanced melanoma: the emulated target trials.

EClinicalMedicine

December 2024

AP-HP Hotel-Dieu Hospital, Centre de Recherche épidémiologie et Statistiques (CRESS-UMR1153), Centre d'épidémiologie Clinique, Inserm / Université Paris Cité / AP-HP, Centre Virchow-Villermé, Centre Equator France, Paris, France.

Background: Immune checkpoint inhibitors (ICIs) have demonstrated their efficacy with a 7.5-year overall survival (OS) close to 50% for advanced stages. The design of clinical trials provides for treatment until progression or toxicity, or for a maximum duration of two years.

View Article and Find Full Text PDF

Background: Cancer-treatment toxicity is common and symptoms must be identified quickly and accurately. Since symptom reporting during consultations is hampered by time constraints and patient/oncologist biases, patient-reported outcome-measure (PROM) questionnaires are useful. A strong shift to at-home cancer treatment has led to growing interest in remote symptom monitoring via electronic-PROMs (ePROMs).

View Article and Find Full Text PDF

Addressing treatment switching in the ALTA-1L trial with g-methods: exploring the impact of model specification.

BMC Med Res Methodol

December 2024

Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), Faculty of Medicine, Ludwig-Maximilians-Universität München, Marchioninistr. 15, 81377, Munich, Germany.

Article Synopsis
  • Treatment switching in clinical trials complicates causal inference, making intention-to-treat (ITT) analyses less reliable for determining the true treatment effect.
  • The ALTA-1L trial on brigatinib versus crizotinib highlighted this issue, showing more promising results for brigatinib when removed from treatment switching scenarios, via methods like Inverse Probability of Censoring Weights (IPCW).
  • Re-analysis using IPCW and g-methods suggested that the treatment effect of brigatinib on overall survival may be significantly better than previously estimated, indicating that standard ITT analysis might underestimate treatment benefits.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!